HomeAI · summaries
Storia in 6 fonti
Argenx Secures Promising Autoimmune Drug In Forte Biosciences Takeover - argenx (NASDAQ:ARGX), Forte Bios
Argenx is acquiring Forte Biosciences in a $2.2 billion all-cash deal. The $77 per share buyout expands its autoimmune drug portfolio.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline
- ·
statnews.com
Argenx to buy Forte Biosciences for $2.2B
Argenx plans to buy Forte Biosciences for $2.2 billion, expanding its pipeline of drugs that could treat multiple autoimmune diseases.
